MSD takes Glenmark to court over sitagliptin ’infringement’

After a few days of reflection, Merck & Co has retaliated against an attack on one of its major markets for diabetes treatments. The company has filed suit in the Delhi High Court against Glenmark for allegedly violating patents concerning its diabetes therapies, Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride), on the Indian market.